Katsuhide Okunishi1, Marc Peters-Golden. 1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 4810--5642, USA.
Abstract
BACKGROUND: Asthma is a common chronic inflammatory disease of the airways characterized by airway obstruction and hyperresponsiveness. Leukotrienes (LTs) are lipid mediators that contribute to many aspects of asthma pathogenesis. As the LT pathway is relatively steroid-resistant, its blockade by alternative strategies is a desirable component of asthma management. Cysteinyl LT (cysLT) receptor 1 antagonists (LTRAs) have been utilized worldwide for more than 10years, and while their efficacy in asthma is well accepted, their limitations are also evident. SCOPE OF REVIEW: In this review, we summarize the biological effects of LTs in asthma, review recent advances in LT receptors, and consider possible new therapeutic targets in the LT pathway that offer the potential to achieve better control of asthma in the future. MAJOR CONCLUSIONS: CysLTs play pathogenetic roles in many aspects of asthma, and blockade of cysLT receptor 1 by currently available LTRAs is certainly beneficial in disease management. On the other hand, the limitations of LTRAs are also apparent. Recent studies have revealed new receptors for cysLTs other than classical cysLT receptors 1 and 2, as well as the potential importance of LTB(4) in asthma. GENERAL SIGNIFICANCE: Recent findings provide clues to new approaches for targeting the LT pathway that may overcome the current limitations of LTRAs and achieve superior control of asthma. This article is part of a Special Issue entitled: Biochemistry of Asthma. 2011 Elsevier B.V. All rights reserved.
BACKGROUND:Asthma is a common chronic inflammatory disease of the airways characterized by airway obstruction and hyperresponsiveness. Leukotrienes (LTs) are lipid mediators that contribute to many aspects of asthma pathogenesis. As the LT pathway is relatively steroid-resistant, its blockade by alternative strategies is a desirable component of asthma management. Cysteinyl LT (cysLT) receptor 1 antagonists (LTRAs) have been utilized worldwide for more than 10years, and while their efficacy in asthma is well accepted, their limitations are also evident. SCOPE OF REVIEW: In this review, we summarize the biological effects of LTs in asthma, review recent advances in LT receptors, and consider possible new therapeutic targets in the LT pathway that offer the potential to achieve better control of asthma in the future. MAJOR CONCLUSIONS: CysLTs play pathogenetic roles in many aspects of asthma, and blockade of cysLT receptor 1 by currently available LTRAs is certainly beneficial in disease management. On the other hand, the limitations of LTRAs are also apparent. Recent studies have revealed new receptors for cysLTs other than classical cysLT receptors 1 and 2, as well as the potential importance of LTB(4) in asthma. GENERAL SIGNIFICANCE: Recent findings provide clues to new approaches for targeting the LT pathway that may overcome the current limitations of LTRAs and achieve superior control of asthma. This article is part of a Special Issue entitled: Biochemistry of Asthma. 2011 Elsevier B.V. All rights reserved.
Authors: B Dahlén; E Nizankowska; A Szczeklik; O Zetterström; G Bochenek; M Kumlin; L Mastalerz; G Pinis; L J Swanson; T I Boodhoo; S Wright; L M Dubé; S E Dahlén Journal: Am J Respir Crit Care Med Date: 1998-04 Impact factor: 21.405
Authors: K R Lynch; G P O'Neill; Q Liu; D S Im; N Sawyer; K M Metters; N Coulombe; M Abramovitz; D J Figueroa; Z Zeng; B M Connolly; C Bai; C P Austin; A Chateauneuf; R Stocco; G M Greig; S Kargman; S B Hooks; E Hosfield; D L Williams; A W Ford-Hutchinson; C T Caskey; J F Evans Journal: Nature Date: 1999-06-24 Impact factor: 49.962
Authors: J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk Journal: Nat Genet Date: 1999-06 Impact factor: 38.330
Authors: J A Leff; W W Busse; D Pearlman; E A Bronsky; J Kemp; L Hendeles; R Dockhorn; S Kundu; J Zhang; B C Seidenberg; T F Reiss Journal: N Engl J Med Date: 1998-07-16 Impact factor: 91.245
Authors: Nikolaos Eleftheriadis; Stephanie A Thee; Martijn R H Zwinderman; Niek G J Leus; Frank J Dekker Journal: Angew Chem Int Ed Engl Date: 2016-09-09 Impact factor: 15.336
Authors: Nikolaos Eleftheriadis; Constantinos G Neochoritis; Niek G J Leus; Petra E van der Wouden; Alexander Dömling; Frank J Dekker Journal: J Med Chem Date: 2015-09-16 Impact factor: 7.446